Literature DB >> 11454557

Contrasting effects of phentolamine and nitroprusside on neural and cardiovascular variability.

P van de Borne1, M Rahnama, S Mezzetti, N Montano, A Porta, J P Degaute, V K Somers.   

Abstract

The relative contributions of a central neural oscillator and of the delay in alpha-adrenergic transmission within the baroreflex loop in the predominance of low-frequency (LF) cardiovascular variability during sympathetic activation in humans are unclear. We measured R-R interval (RR), muscle sympathetic nerve activity (MSNA), blood pressure (BP), and their variability in 10 normal subjects during sympathetic activation achieved by BP lowering with sodium nitroprusside (SNP) and alpha-adrenergic blockade using phentolamine. SNP and phentolamine induced comparable reductions in BP (P > 0.25). Despite tachycardia and sympathetic activation with both SNP and phentolamine, LF variability in RR, MSNA, and BP increased during SNP and decreased during phentolamine (SNP: RR +20 +/- 6%, MSNA +3 +/- 5%, systolic BP +9 +/- 6%, diastolic BP +7 +/- 5%; phentolamine: RR -2 +/- 7%, MSNA -34 +/- 6%, systolic BP -16 +/- 8%, diastolic BP -13 +/- 4%, P < 0.05 except systolic BP, where P = 0.09). Thus LF variability is reduced when sympathetic activation is induced by alpha-adrenergic blockade. This suggests that alpha-adrenergic transmission within the baroreflex loop may contribute importantly to the predominance of LF cardiovascular variability associated with sympathetic excitation in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11454557     DOI: 10.1152/ajpheart.2001.281.2.H559

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  7 in total

1.  Effects of aerobic conditioning on cardiovascular sympathetic response to and recovery from challenge.

Authors:  M Lindgren; C Alex; P A Shapiro; P S McKinley; E N Brondolo; M M Myers; C J Choi; S Lopez-Pintado; R P Sloan
Journal:  Psychophysiology       Date:  2013-07-28       Impact factor: 4.016

2.  The Effect of Hostility Reduction on Autonomic Control of the Heart and Vasculature: A Randomized Controlled Trial.

Authors:  Parisa Hajjari; Sara Mattsson; Kathleen M McIntyre; Paula S McKinley; Peter A Shapiro; Ethan E Gorenstein; Felice A Tager; Chien-Wen J Choi; Seonjoo Lee; Richard P Sloan
Journal:  Psychosom Med       Date:  2016-05       Impact factor: 4.312

3.  Aerobic exercise and strength training effects on cardiovascular sympathetic function in healthy adults: a randomized controlled trial.

Authors:  Christian Alex; Martin Lindgren; Peter A Shapiro; Paula S McKinley; Elizabeth N Brondolo; Michael M Myers; Yihong Zhao; Richard P Sloan
Journal:  Psychosom Med       Date:  2013-04-29       Impact factor: 4.312

Review 4.  Short-term cardiovascular oscillations in man: measuring and modelling the physiologies.

Authors:  Michael A Cohen; J Andrew Taylor
Journal:  J Physiol       Date:  2002-08-01       Impact factor: 5.182

5.  Oscillatory behavior of ventricular action potential duration in heart failure patients at respiratory rate and low frequency.

Authors:  Ben Hanson; Nick Child; Stefan Van Duijvenboden; Michele Orini; Zhong Chen; Ruben Coronel; Christopher A Rinaldi; Jaspal S Gill; Jaswinder S Gill; Peter Taggart
Journal:  Front Physiol       Date:  2014-10-28       Impact factor: 4.566

Review 6.  Assessing low-frequency oscillations in cerebrovascular diseases and related conditions with near-infrared spectroscopy: a plausible method for evaluating cerebral autoregulation?

Authors:  Adam Vittrup Andersen; Sofie Amalie Simonsen; Henrik Winther Schytz; Helle Klingenberg Iversen
Journal:  Neurophotonics       Date:  2018-09-18       Impact factor: 3.593

7.  Use of Mayer wave activity to demonstrate aberrant cardiovascular autonomic control following sports concussion injury.

Authors:  Michael F La Fountaine; Asante N Hohn; Caroline L Leahy; Anthony J Testa; Joseph P Weir
Journal:  Ann N Y Acad Sci       Date:  2021-09-03       Impact factor: 6.499

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.